Premium
Endocrine therapy for recurrence after definitive radiotherapy in patients with prostate cancer
Author(s) -
Furuya Yuzo,
Akakura Koichiro,
Tanaka Masashi,
Ichikawa Tomohiko,
Igarashi Tatsuo,
Murakami Shino,
Ito Haruo
Publication year - 2001
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1046/j.1442-2042.2001.00288.x
Subject(s) - medicine , endocrine system , radiation therapy , prostate cancer , oncology , cancer , univariate analysis , prostate , prostate specific antigen , urology , hormone , multivariate analysis
Background: Long‐term results were analyzed to evaluate the role of endocrine therapy in the management of local and distant recurrence of prostate cancer following external radiation therapy. Methods: Between 1976 and 1994, 92 patients with untreated prostate cancer underwent external beam radiation therapy alone. Endocrine therapy had been started when relapse was evident. Results: Failure was seen in 35 of 92 patients: 10 local, 19 distant and six biochemical failures. Endocrine treatment was performed in 28 patients with nine local and 19 distant failures. The cancer‐specific survival rate from the endocrine treatment was 54.5% at 5 years. Prostate‐specific antigen level in 20 of 20 patients (100%) decreased to below the normal limit 3 months after the start of endocrine therapy. In univariate analysis, T classification was the most significant variable for cancer‐specific survival from the initial treatment. Conclusions: A favorable outcome was achieved by endocrine therapy in patients who had relapsed after external beam radiation monotherapy. Even the recurrent tumor had a sensitivity to androgen. Patients with locally advanced disease (T2b and T3) had poorer prognosis than those with minimally extended disease (T1b and T2a).